Abbott Laboratories company logo

# 1st Gen Model Abbott Laboratories Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 18, 2017
Deal entry on
Dec. 18, 2017
0.64%Expected margin
54.65% successful of 86 deals
$55.50 Last close price
at 15-dec-2017

ABT

Model's trade recommendations 2.62% Return for period

-7.72% Annual return

$96.60B Market Cap

β 1.06  

ABT

Model (following trade recommendations)

ABT

Underlying stock

S&P 500

Index
Return for period 2.62%
-0.11%
1.78%
52wk return -22.30%
45.67%
16.82%
52wk Range
38.10—56.37
2000.54—2399.63
Sortino ratio -0.93
Sharpe ratio -0.77
Norm. RMSE 0.15%
Downside risk 8.39%
Volatility 10.19%
  • 1.06 (1.91%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Abbott Laboratories (ABT) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABT model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1727M
P/E 23.03
Shares Outstanding 1741M
% Held by Insiders 0.76%
% Held by Institutions 71.32%
EPS (last reported FY) $2.20
EPS (last reported Q) $0.66
EPS, estimated (last reported Q) $0.65
Total revenues $21 B
Net income $1 B